If you have been reading about thymosin beta-4 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-27. Numbers and descriptions here follow the published literature rather than marketing material.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
=== Mines === Mark 5 Anti-Tank Mine Mark 7 Anti-Tank Mine L2A1 Light Non-Metallic Anti-Tank Mine L9, L17, and L18 "Bar" Anti-Tank Mine L3A1 Non-Metallic Anti-Tank Mine L14A1 Anti-Tank Mine Mark 2 Anti-Personnel Mine No. 5 Anti-Personnel Mine No. 6 Anti-Personnel Mine C3 Non-Metallic Anti-Personnel Mine M18A1 Anti-Personnel Mine L1E1 Area Defence Projector
For services to Music. David Wilkinson Cawthra, lately Director, Infrastructure Services Privatisation, British Railways Board. For services to the Railway Industry. Honor Mary Ruth Chapman, Partner, Jones Lang Wootton. For services to the Property Industry. William Herman MacKillop Clark, lately Head, Operational Re-organisation Division, Crown Prosecution Service. Owen J. D. Clarke, Controller, Scotland, Board of Inland Revenue. Stella Rosemary Clarke, . For services to the Community in Bristol. Betty St. Clair, The Honourable Mrs. Clay. For services to Guiding. John Brian Clayton, Chairman, Bridon plc. For services to Industry and to Export. Donald Thomas Younger Curry, Chairman, Meat and Livestock Commission. For services to Agriculture. William Wentworth Daniel. For services for Industrial Relations. Edward Charles Dart, Research and Development Director, Zeneca Seeds. For services to Industry and to Science. Edmund Leopold de Rothschild, . For charitable services. Nicholas Dampier Deakin. For services to the Commission on the Future of the Voluntary Sector. Anthony Albert Denton, Chairman, Noble Denton International Ltd. For services to Engineering. Roger Joseph Dickens, , Deputy U.K Senior Partner, KPMG. For services to Industry in the West Midlands. Judith Donovan, Chair, Bradford & District Training and Enterprise Council. For services to Training. Olga Lindholm Driver, Senior Partner, Aiking Driver Partnership. For services to ACAS and to Industrial Relations. Francis Cuthbert Duffy. For services to Architecture. Professor John Edwin Enderby, , lately H. O.
In the aftermath, Naram-Sin deified himself as well as posthumously deifying Sargon and Manishtushu but not his uncle Rimush. The echoes of the revolt were reflected in later Sumerian literary compositions such as the Great Revolt against Naram-Sin, "Naram-Sin and the Enemy Hordes" and "Gula-AN and the Seventeen Kings against Naram-Sin".
=== History === The Local Government Act 1888 reformed English local government by creating administrative counties, county boroughs, and elected county councils and county borough councils to govern them. County boroughs largely consisted of those settlements with a population over 50,000, and administrative counties covered smaller towns and rural areas. The three ridings of Yorkshire were reconstituted as the administrative counties of County of York, East Riding, County of York, North Riding, and County of York, West Riding. Within what would later become West Yorkshire, Bradford, Halifax, Huddersfield, and Leeds were made county boroughs. The Local Government Act 1972, which came into effect in 1974, reformed English local government again. It introduced metropolitan counties, which covered the largest urban areas, and non-metropolitan counties elsewhere. The metropolitan county of West Yorkshire was created from the central part of the West Riding and divided into five metropolitan boroughs. The provision of local government services was divided between West Yorkshire County Council and the district councils of the five boroughs. In Local Government Act 1985, which came into effect the following year, abolished the county council and transferred many of its powers and responsibilities the borough councils. It also created or allowed to be created joint bodies, notably the West Yorkshire Passenger Transport Executive, in which all the borough councils participated.
Sources: en.wikipedia.org
They are not exposed on cell membranes, but are found in internal membranes, where they assist with the loading of antigenic peptides onto classic MHC class II molecules. The important nonclassical MHC class II molecule DM is only found from the evolutionary level of lungfish, although also in more primitive fishes both classical and nonclassical MHC class II are found.
Signs of breast cancer may include a lump in the breast, a change in breast shape, dimpling of the skin, milk rejection, fluid coming from the nipple, a newly inverted nipple, or a red or scaly patch of skin. In those with distant spread of the disease, there may be bone pain, swollen lymph nodes, shortness of breath, or yellow skin. Risk factors for developing breast cancer include obesity, a lack of physical exercise, alcohol consumption, hormone replacement therapy during menopause, ionizing radiation, an early age at first menstruation, having children late in life (or not at all), older age, having a prior history of breast cancer, and a family history of breast cancer. About five to ten percent of cases are the result of an inherited genetic predisposition, including BRCA mutations among others. Breast cancer most commonly develops in cells from the lining of milk ducts and the lobules that supply these ducts with milk. Cancers developing from the ducts are known as ductal carcinomas, while those developing from lobules are known as lobular carcinomas. There are more than 18 other sub-types of breast cancer. Some, such as ductal carcinoma in situ, develop from pre-invasive lesions. The diagnosis of breast cancer is confirmed by taking a biopsy of the concerning tissue. Once the diagnosis is made, further tests are carried out to determine if the cancer has spread beyond the breast and which treatments are most likely to be effective.
== Dynacare in Alberta, Canada == The 1994 Alberta Regional Health Authorities Act had created "new opportunities for contracting out both the management and delivery of public healthcare services to private business in lieu of public or non-profit agencies." The Regional Health Authorities that were created through the 1994 Act, were given the authority to "create subsidiary corporations and delegate responsibilities, powers and duties to either public, private or hybrid agencies." In response to 1994 Act, Dynacare Kasper Medical Laboratories and MDS Kasper in southern Alberta, merged into "two large corporate entities or virtual private monopolies for contracting purposes." A 2009 Alberta Consumers Association report raised concerns that this merger had left "smaller companies out in the cold". Concerns were raised in the fall of 2020, when Alberta Premier "took the first big step toward privatization in health care" by outsourcing public health sector jobs. The next cuts will be in community lab testing, where "about 2,000 workers are expected to “transition” to the private provider." At the same time that Premier Kenney was announcing privatization plans, Pincock came to Calgary to announce that DynaLIFE would be offering paid voluntary COVID-19 tests for departing travellers at $150 per test. The Calgary Herald said that DynaLIFE is the preferred choice for Alberta's private lab services when the public health service is outsourced.
== Drug development == It is hypothesized that the kynurenine pathway is partly responsible for the therapeutic effect of lithium on bipolar disorder. If that is the case, it could be a target of drug discovery.
The system draws water from below into the material. The water diffuses into the higher layer, where it evaporates, leaving behind any contaminants. The vapor condenses on top, where it can be captured. The film is produced by repeatedly adding a fluid coating that hardens. Bacteria produce nanocellulose fibers with interspersed graphene oxide flakes. The film is light and easily manufactured at scale.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
Short transit at ambient temperature is generally tolerated, but long-term storage at room temperature is not recommended. Heat, moisture, and light all accelerate degradation. Cold, dry, dark storage is the conventional choice.